The seven main types of chemotherapy are alkylating agents, antimetabolites, antitumor antibiotics, topoisomerase inhibitors, mitotic inhibitors, corticosteroids, and miscellaneous agents. Each class attacks cancer cells through a different mechanism, and most treatment plans combine drugs from multiple categories to improve effectiveness. These categories cover traditional chemotherapy, which works by killing fast-dividing cells. Targeted therapies and immunotherapies are separate treatment types, not subtypes of chemo.
Alkylating Agents
Alkylating agents were among the first chemotherapy drugs developed, and they remain widely used today. They work by chemically attaching small molecular groups to the DNA inside cancer cells. These groups create cross-links between the two strands of the DNA double helix, essentially gluing them together so they can’t separate when the cell tries to divide. Because the cell can’t copy its DNA, it can’t reproduce, and it dies.
This class includes several subgroups: nitrogen mustards, platinum compounds, nitrosoureas, alkyl sulfonates, and triazenes. Alkylating agents are particularly effective against slow-growing cancers, including solid tumors and certain leukemias. One downside is that they don’t distinguish perfectly between cancer cells and normal fast-dividing cells, which is why side effects like low blood counts are common.
Antimetabolites
Antimetabolites are designed to look like the natural building blocks cells need to make DNA and RNA. Because they’re close enough in structure to fool the cell’s machinery, they get incorporated into genetic material or block the enzymes responsible for assembling it. The result is DNA that’s nonfunctional, with strand breaks or incomplete chains that prevent the cell from dividing.
There are three main subtypes based on which building block they mimic. Folic acid antagonists, including methotrexate and 5-fluorouracil, block an essential step in DNA synthesis. Purine antagonists like mercaptopurine substitute for one type of DNA base. Pyrimidine antagonists like gemcitabine substitute for another. Because antimetabolites primarily disrupt DNA copying, they’re most active during the phase of the cell cycle when DNA is being synthesized. This makes them especially useful against cancers with a high proportion of actively dividing cells.
Antitumor Antibiotics
Despite the name, antitumor antibiotics aren’t used to treat infections. They’re derived from natural substances produced by certain soil fungi, and they kill cancer cells by interfering with the enzymes that manage DNA structure. The most important subgroup is the anthracyclines, which include doxorubicin and daunorubicin.
Anthracyclines wedge themselves between the base pairs of DNA, a process called intercalation. This distorts the shape of the DNA strand and interferes with an enzyme called topoisomerase II, which normally repairs breaks in DNA. When the drug, the enzyme, and the DNA are all bound together, the strand breaks aren’t repaired and the cell dies. Anthracyclines also generate free radicals, highly reactive molecules that cause additional chemical damage to cell structures. Because of this dual mechanism, anthracyclines are among the most potent chemotherapy drugs available, but they can also damage heart muscle over time, which limits how much a patient can receive over their lifetime.
Topoisomerase Inhibitors
Your DNA is tightly coiled, and every time a cell needs to read or copy it, enzymes called topoisomerases must cut, unwind, and reseal the strands. Topoisomerase inhibitors block the resealing step, leaving permanent breaks in the DNA that trigger the cell to self-destruct.
There are two subtypes. Type I inhibitors target the enzyme that cuts a single DNA strand during unwinding. Type II inhibitors target the version that cuts both strands simultaneously. The distinction matters because different cancers respond better to one type or the other. While antitumor antibiotics like doxorubicin also affect topoisomerase II, the drugs in this standalone category work through slightly different binding interactions and are used in different clinical contexts.
Mitotic Inhibitors
Mitotic inhibitors stop cancer cells during the final stage of division, when the cell physically splits in two. This process depends on tiny protein tubes called microtubules, which act like scaffolding to pull the cell’s duplicated chromosomes apart. Mitotic inhibitors sabotage this scaffolding, but they do it in two opposite ways.
Taxanes lock microtubules into a rigid, overstabilized state. They promote the assembly of the protein tubes and then prevent them from disassembling, so the cell gets stuck mid-division. It’s like building scaffolding you can never take down. Vinca alkaloids do the reverse: they prevent microtubules from forming in the first place by breaking apart the protein subunits and blocking new assembly. Either way, the chromosomes can’t be properly separated, the cell cycle stalls, and the cell eventually dies. Because these drugs are only active during the division phase, they tend to work best against cancers that are dividing rapidly.
Corticosteroids
Corticosteroids occupy an unusual place in chemotherapy. They’re synthetic versions of hormones your body naturally produces, and they have broad effects on inflammation and immune function. In cancer treatment, they serve a dual role: they directly kill certain cancer cells, and they reduce side effects caused by other chemotherapy drugs.
Their direct anticancer effect is strongest in blood cancers. In acute lymphoblastic leukemia, corticosteroids are a core part of treatment because they trigger the death of cancerous white blood cells. They’re also used in treatment protocols for lymphomas and multiple myeloma. Beyond killing cancer cells, corticosteroids help control nausea, reduce swelling around tumors, and prevent allergic reactions to other chemo drugs. This makes them one of the most commonly prescribed supportive medications in oncology, even when they aren’t the primary cancer-fighting agent.
Miscellaneous Agents
Some chemotherapy drugs don’t fit neatly into any of the six categories above because they work through unique or overlapping mechanisms. Rather than force them into an existing class, oncology groups them together as miscellaneous agents. Examples include asparaginase, which starves cancer cells by breaking down an amino acid they depend on, and all-trans-retinoic acid, which forces immature leukemia cells to mature into normal cells instead of multiplying out of control. Other drugs in this category include arsenic trioxide, procarbazine, and romidepsin.
These drugs are typically used for specific cancer types rather than as broad-spectrum treatments. Asparaginase, for example, is used almost exclusively in acute lymphoblastic leukemia, while romidepsin targets certain rare lymphomas.
How Chemotherapy Is Given
Most chemotherapy is delivered intravenously, through a vein, because it allows the drug to enter the bloodstream quickly and reach cancer cells throughout the body. Some drugs are available as pills, capsules, or liquids you can take by mouth, which is more convenient but isn’t possible for every drug. Certain medications would be destroyed by stomach acid before they could be absorbed, while others would damage the stomach lining.
Less common routes are used when doctors need to target a specific area. Intrathecal chemotherapy delivers drugs directly into the fluid surrounding the brain and spinal cord. Intraperitoneal chemotherapy goes into the abdominal cavity. Topical chemotherapy is applied as a cream for skin cancers. The route depends on the drug, the cancer’s location, and how well the drug can reach the tumor through the bloodstream alone.
Why Treatments Combine Multiple Types
Most chemotherapy regimens use drugs from two or more of these categories at once. The logic is straightforward: cancer cells in a tumor aren’t all in the same phase of their growth cycle at the same time. A mitotic inhibitor catches cells that are actively dividing, while an alkylating agent can damage DNA in cells that are preparing to divide later. By hitting the cancer through multiple mechanisms simultaneously, combination therapy reduces the chance that resistant cells survive and regrow. It also allows lower doses of each individual drug, which can reduce the severity of side effects from any single agent.